Implementation of a Teleophthalmology Screening Network Using a Novel Handheld Fundus Camera on a Remote Island: Physician and Patient Perceptions from Real World Experience (Preprint)

2020 ◽  
Author(s):  
Tsai-Chu Yeh ◽  
Kang-Jung Lo ◽  
De-Kuang Hwang ◽  
Tai-Chi Lin ◽  
Yu-Bai Chou

BACKGROUND While teleophthalmology is gaining traction in recent years, it is taking center stage in the COVID-19 pandemics. However, most hospitals are yet ready due to a severe lack of real-world experience. Furthermore, there are limited number of studies evaluating the telemedicine application on remote islands. OBJECTIVE To evaluate the real-world clinical and referral accuracy, image quality, physician perceived diagnostic certainty, and patient satisfaction of a telemedicine eye screening using a novel handheld fundus camera in a rural and medically underserved population. METHODS This prospective study enrolled 176 eyes from a remote island. All participants underwent a comprehensive ophthalmic examination. Nonmydriatic retinal images obtained using a handheld fundus camera were reviewed by two retinal specialists to determine the image quality, diagnosis, and need for referrals. The agreement of diagnosis between image-based assessments was compared to that of binocular indirect ophthalmoscopic assessment. RESULTS Image quality of fundus photograph was considered ideal or acceptable in 97.7% and 95.5% eyes. There was considerable agreement in diagnosis between the indirect ophthalmoscopic assessment and image-based assessment by two reviewers (Cohen’s kappa=0.80 and 0.78, respectively). Likewise, substantial agreement in referrals was achieved. The sensitivity for referable retinopathy from the two reviewers was 78% [95% CI, 57%-91%] and 78% [95% CI, 57%-91%], whereas specificity was 99% [95% CI, 95%-99%] and 98% [95% CI, 93%-99%], respectively. For physician perceived certainty in diagnosis, 93.8% and 90.3% were considered either certain or reliable. Overall, 97.4% of participants were satisfied with their experience and greatly valued the telemedicine service. CONCLUSIONS The novel fundus camera-based telemedicine screening demonstrated high accuracy in detecting clinically significant retinopathy in real-world settings. It achieved high patient satisfaction and physician perceived certainty in diagnosis with reliable image quality, which may be scaled internationally to overcome the geographical barriers under global pandemic. CLINICALTRIAL N/A

Author(s):  
Patrick Derigs ◽  
Aleksandar Radujkovic ◽  
Maria-Luisa Schubert ◽  
Paul Schnitzler ◽  
Tilman Schöning ◽  
...  

AbstractMorbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT) are still essentially affected by reactivation of cytomegalovirus (CMV). We evaluated 80 seropositive patients transplanted consecutively between March 2018 and March 2019 who received letermovir (LET) prophylaxis from engraftment until day +100 and retrospectively compared them with 80 patients without LET allografted between January 2017 and March 2018. The primary endpoint of this study was the cumulative incidence (CI) of clinically significant CMV infection (CS-CMVi) defined as CMV reactivation demanding preemptive treatment or CMV disease. With 14% CI of CS-CMVi at day +100 (11 events) was significantly lower in the LET cohort when compared to the control group (33 events, 41%; HR 0.29; p < 0.001). Whereas therapy with foscarnet could be completely avoided in the LET group, 7 out of 80 patients in the control cohort received foscarnet, resulting in 151 extra in-patient days for foscarnet administration (p = 0.002). One-year overall survival was 72% in the control arm vs 84% in the LET arm (HR 0.75 [95%CI 0.43–1.30]; p < 0.306). This study confirms efficacy and safety of LET for prophylaxis of CS-CMVi after alloHCT in a real-world setting, resulting in a significant patient benefit by reducing hospitalization needs and exposure to potentially toxic antiviral drugs for treatment of CMV reactivation.


Ultrasound ◽  
2020 ◽  
pp. 1742271X2094574
Author(s):  
Nicholas J Dudley

It is important to understand the uncertainty in fetal measurements when using them in the management of pregnancy. The aim of this essay is to provide background on errors and uncertainty, describing error sources and their potential impact, with guidance on improving accuracy. Errors can be systematic or random, arising from equipment, image plane selection, measurement method and caliper placement and influenced by image quality, training and experience. The uncertainty in measurements is larger than clinically significant differences in fetal size and growth. Errors can be reduced by implementing equipment acceptance testing, written procedures, training and audit.


2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 196-196 ◽  
Author(s):  
Geoffrey Gotto ◽  
Vincent Fradet ◽  
Darrel Drachenberg ◽  
Robert Sabbagh ◽  
Ricardo A. Rendon ◽  
...  

196 Background: Oral androgen biosynthesis inhibitor, abiraterone acetate plus prednisone (AA+P), has shown to improve survival and patient-related outcomes (PROs) in clinical trials. The COSMiC study (Canadian Observational Study in Metastatic Cancer of the Prostate; ClinicalTrials.gov: NCT02364531) set out to prospectively amass real-world data on mCRPC patients (pts) managed with AA+P in communities within Canada. Here, we report the interim analysis of their PROs. Methods: At planned data cutoff in Sept 2017 after a median follow-up of 33.8 months, 264 pts were enrolled in 39 sites across Canada. Their FACT-P (Functional Assessment of Cancer Therapy – Prostate) and MoCA (Montreal Cognitive Assessment) were evaluated at baseline as well as at weeks 12, 24, 48 and 72 after AA+P initiation. A 10-point decrease denotes clinically significant degradation in FACT-P and a total MoCA score of > = 26 is considered normal. Descriptive analysis was utilized with continuous variables. Changes from baseline were summarized using mean (SD). Results: At a median age of 77 among 264 pts, 230, 185, 110 and 63 pts were available for analysis at their week 12, 24, 48, and 72 assessments respectively. The mean baseline FACT-P total score was 111.2 (19.44) with a < 3-point absolute change from baseline at subsequent assessments, denoting no clinically significant change in functional status over time. The mean baseline MoCA score was 25.2 (4.50), yet all subsequent assessments scored above 26 and a mean absolute change from baseline of < 1, showing an absence of cognitive decline over time. PSA value was available for 221 pts, 64.3% (142/221) and 34.4% (76/221) achieved a PSA decline of > 50% and 90% respectively. All-grade treatment-related adverse events were reported in 63 pts, with 11% who have had AA+P discontinuation or interruption. Conclusions: COSMiC represents the largest Canadian mCRPC cohort treated with AA+P with real world prospective evaluation of PROs. This data demonstrated the maintenance in quality of life and cognitive status over the course of the study, and underscores the importance of PRO utilization in this complex patient population. Clinical trial information: NCT02364531.


2018 ◽  
Vol 33 (10) ◽  
pp. 1768-1773 ◽  
Author(s):  
Kathryn A. Martinez ◽  
Mark Rood ◽  
Nikhyl Jhangiani ◽  
Lei Kou ◽  
Susannah Rose ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document